glp-1 coverage medicare covers GLP-1s to treat diabetes and some other health conditions, including obstructive sleep apnea and cardiovascular disease, but not obesity GLP-1s and The Payer Predicament

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes

GLP-1 RAs: Head-to-Head Comparisons When discussing all of the popular options in GLP-1 drugs its crucial to appreciate the diversity within this class of drugs

Diabetes 62, 23802385

If you do not meet clinical criteria or the provider determines GLP-1 medications are not appropriate for your situation, you will not receive a prescription

The FDA provided enforcement discretion periods: 503A pharmacies (like Belmar's patient-specific facilities) could continue compounding semaglutide until April 22, 2025, while 503B outsourcing facilities had until May 22, 2025

Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, et al